SMITH & NEPHEW PLC Smith & Nephew plc Share Price Deutsche Boerse AG
Equities
NPWA
US83175M2052
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.6 EUR | -0.84% |
|
+1.72% | -4.07% |
| Sales 2024 * | 5.82B 5.35B 459B | Sales 2025 * | 6.12B 5.63B 483B | Capitalization | 11.27B 10.36B 889B |
|---|---|---|---|---|---|
| Net income 2024 * | 541M 498M 42.69B | Net income 2025 * | 694M 638M 54.76B | EV / Sales 2024 * | 2.38 x |
| Net Debt 2024 * | 2.56B 2.35B 202B | Net Debt 2025 * | 2.23B 2.05B 176B | EV / Sales 2025 * | 2.21 x |
| P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
16.8
x | Employees | 18,452 |
| Yield 2024 * |
2.96% | Yield 2025 * |
3.32% | Free-Float | 99.15% |
More Fundamentals
* Assessed data
More news
Latest transcript on Smith & Nephew plc
More recommendations
More press releases
More news
| 1 day | -0.84% | ||
| 1 week | +1.72% | ||
| Current month | +3.51% | ||
| 1 month | +5.36% | ||
| 3 months | -9.23% | ||
| Current year | -4.07% |
1 week
23.20
23.80
1 month
22.2023.80
Current year
22.2026.60
1 year
20.2029.80
3 years
20.2037.40
5 years
20.2047.60
10 years
20.2047.60
| Managers | Title | Age | Since |
|---|---|---|---|
Deepak Nath
CEO | Chief Executive Officer | - | 31/03/22 |
John Rogers
DFI | Director of Finance/CFO | 56 | 11-30 |
Alison Parkes
CMP | Compliance Officer | - | 31/03/99 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Marc E. Owen
BRD | Director/Board Member | 65 | 30/09/17 |
Jeremy Maiden
BRD | Director/Board Member | 62 | 13/09/23 |
Rupert Soames
CHM | Chairman | 63 | 25/04/23 |
| Date | Price | Change |
|---|---|---|
| 16/05/24 | 23.6 | -0.84% |
| 15/05/24 | 23.8 | +2.59% |
| 14/05/24 | 23.2 | -0.85% |
| 13/05/24 | 23.4 | +0.86% |
| 10/05/24 | 23.2 | 0.00% |
Delayed Quote Deutsche Boerse AG, May 16, 2024 at 07:03 am
More quotes
Smith & Nephew Plc specializes in designing, manufacturing and marketing medical products and equipment. Net sales break down by activity sector as follows:
- orthopedic surgery (39.9%): primarily orthopedic implants (hips, knees and shoulders);
- sports medicine, arthroscopy and cervicofacial surgery (31.2%): surgery and damaged tissue repair products and instruments, visualization products, etc.;
- wound care (28.9%): skin grafts for major burns victims, treatments for leg ulcers, etc.
The United States accounts for 53.7% of net sales.
Calendar
24/07/2024
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
12.92
USD
Average target price
16.35
USD
Spread / Average Target
+26.49%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +10.86% | 126B | |
| +4.17% | 9.12B | |
| +40.13% | 5.61B | |
| -21.47% | 4.75B | |
| +8.77% | 3.45B | |
| -6.03% | 2.89B | |
| -12.05% | 2.07B | |
| -7.83% | 2.05B | |
| -22.84% | 1.8B |
- Stock Market
- Equities
- SN. Stock
- NPWA Stock
